KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion

Annals of Surgical Oncology
Junichi ShindohNorihiro Kokudo

Abstract

The KRAS mutation status is reportedly correlated with poor survival outcome in patients with colorectal liver metastases (CLM); however, its true prognostic impact and the reason for the poor prognosis remain unclear. Data on 163 patients with a known KRAS mutation status who underwent curative resection for CLM were retrospectively reviewed. The long-term survival and site-specific incidence of recurrence were then compared between patients with a KRAS mutation (mtKRAS) and those without a mutation (wtKRAS). The mtKRAS group had a poorer 3-year disease-specific survival (DSS) rate (59.8 vs. 83.6 %, p = 0.016), 3-year recurrence-free survival (RFS) rate (0 vs. 20.2 %, p = 0.069), and median time to surgical failure (TSF) [18.8 vs. 39.7 months, p = 0.001] than the wtKRAS group. The cumulative incidences of liver recurrence and lung recurrence at 3 years were also higher in the mtKRAS group (76.2 vs. 54.7 %, p = 0.060; and 71.9 vs. 37.3 %, p < 0.001, respectively). A multivariate analysis confirmed that an mtKRAS status had a significant effect on the DSS rate (hazard ratio [HR] 2.9, p = 0.006), RFS (HR 2.0, p = 0.004), TSF (HR 2.4, p < 0.001), liver recurrence (HR 1.7, p < 0.001), and lung recurrence (HR 2.6, p < 0.001). Lung-r...Continue Reading

References

Jun 22, 2000·International Journal of Cancer. Journal International Du Cancer·K SchrammE D Kreuser
Sep 5, 2001·British Journal of Cancer·H J AndreyevN Urosevic
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Randolph HechtRafael G Amado
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott KopetzRobert R McWilliams
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan D RichmanPhilip Quirke
Jan 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeanne TieOliver M Sieber
Mar 5, 2011·Current Oncology Reports·Ben George, Scott Kopetz
Oct 3, 2012·The British Journal of Surgery·S StremitzerT Gruenberger
Jun 14, 2014·Journal of the National Cancer Institute·Wilson I GonsalvesUNKNOWN Alliance for Clinical Trials in Oncology
Jul 25, 2015·The British Journal of Surgery·K W BrudvikJ-N Vauthey

❮ Previous
Next ❯

Citations

Feb 20, 2019·Journal of Surgical Oncology·Georgios A MargonisMatthew J Weiss
Feb 10, 2019·Journal of Personalized Medicine·Stergios BoussiosNicholas Pavlidis
Jul 31, 2020·World Journal of Clinical Oncology·George BinghamReza Mirnezami
Oct 7, 2021·Journal of Hepato-biliary-pancreatic Sciences·Neda AminiRichard Andrew Burkhart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.